Article
Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2017
Zhao Eric Y, Shen Yaoqing, Pleasance Erin, Kasaian Katayoon, Leelakumari Sreeja, Jones Martin, Bose Pinaki, Ch'ng Carolyn, Reisle Caralyn, Eirew Peter, Corbett Richard, Mungall Karen L, Thiessen Nina, Ma Yussanne, Schein Jacqueline E, Mungall Andrew J, Zhao Yongjun, Moore Richard A, Den Brok Wendie, Wilson Sheridan, Villa Diego, Shenkier Tamara, Lohrisch Caroline, Chia Stephen, Yip Stephen, Gelmon Karen, Lim Howard, Renouf Daniel, Sun Sophie, Schrader Kasmintan A, Young Sean, Bosdet Ian, Karsan Aly, Laskin Janessa, Marra Marco A, Jones Steven J M
Abstract excerpt
Purpose: Recent studies have identified mutation signatures of homologous recombination deficiency (HRD) in over 20% of breast cancers, as well as pancreatic, ovarian, and gastric cancers. There is an urgent need to understand the clinical implications of HRD signatures. Whereas BRCA1/2 mutations confer sensitivity to platinum-based chemotherapies, it is not yet clear whether mutation signatures can independently...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.